Gastrointestinal Drug Discoveries : Market Research Report

Gastrointestinal Drug Discoveries

Published by: Espicom Healthcare Intelligence

Published: Jan. 15, 2008 - 148 Pages

Foreword
Executive Summary
Inflammatory Bowel Disease
What is inflammatory bowel disease?
Risk factors in the development of IBD
Where in the world?
The IBD therapy market
IBD management
Current treatment options: Aminosalicylates; Sulphasalazine; Oral Mesalamine; Topical Mesalamine; Olsalazine; Balsalazide; Corticosteroids; Prednisone; Budesonide; Hydrocortisone; Immunosuppressants; 6-mercaptopurine; Azathioprine; Cyclosporine; Methotrexate; Tumour necrosis factor alpha inhibitors
What’s in the pipeline?: Potential new drugs for IBD
Competitor ratio analysis
Tumour necrosis factor alpha inhibitors: Remicade (infliximab); Sales forecast; Clinical trial results; Paediatric Crohn’s Disease; Ulcerative Colitis; Humira (adalimumab); Sales forecast
Competitor ratio analysis: Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class
Clinical trial results: CHARM; GAIN; CLASSIC
Cimzia (certolizumab pegol): Sales forecast and assumptions; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; PRECiSE clinical trial programme
RDP58 (delmitide): Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
Golimumab: Sales forecast and assumptions; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class
Cell adhesion molecule inhibitors: Tysabri (natalizumab); Sales forecast and assumptions; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class
Clinical trial results: ENACT-1/ENACT-2; ENCORE
Alicaforsen: Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; Phase II
Firategrast (SB683699): Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
MLN0002: Sales forecast and assumptions; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
Novel corticosteroids: COLAL-PRED (prednisolone); Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; Phase II trial for UC
T-cell modulators: Nuvion (visilizumab); Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; Orencia (abatacept); Sales forecast and assumptions; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class
Immune system modulators: Alequel; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
Interleukin inhibitors: ABT-874; Sales forecast and assumptions; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; Cohort 1/2
STA-5326: Sales forecast and assumptions; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
MAP kinase inhibitors: Semapimod; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
Others: Traficet-EN; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
AST-120: Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
HMPL-004: Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; Promising early-stage development candidates
Irritable Bowel Syndrome
What is irritable bowel syndrome?
Where in the world?
The IBS therapy market
IBS management
Current treatment options: Antispasmodics; Laxatives; Antidiarrhoeal agents; Antidepressants; Serotonergic agents
What’s in the pipeline?: Potential new drugs for IBS
Competitor ratio analysis
Serotonergic Agents: Lotronex (alosetron); Clinical trial results; Zelnorm (tegaserod); Sales forecast; Clinical trial results; IBS with mixed bowel pattern; DDP225; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; DDP733; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; Renzapride; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
Others: Amitiza (lubiprostone); Sales forecast and assumptions; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
Linaclotide acetate: Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
Dexloxiglumide: Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; DARWIN
Dextofisopam: Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
Xifaxan (rifaximin): Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
Crofelemer: Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
Gastro-oesophageal Reflux Disease
What is gastro-oesophageal reflux disease?
The GORD therapy market
GORD management
H2 receptor antagonists: Pepcid/Gaster (famotidine); Sales forecast; Zantac (ranitidine); Sales forecast; Axid (nizatidine); Tagamet (cimetidine)
Proton pump inhibitors: AcipHex/Pariet (rabeprazole); Sales forecast; Nexium (esomeprazole); Sales forecast; Prevacid (lansoprazole); Sales forecast; Losec/Prilosec (omeprazole); Sales forecast; Protonix (pantoprazole); Sales forecast
What’s in the pipeline?
Competitor ratio analysis: Potential new drugs for GORD
ATI-7505: Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; DDP733; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; OX 17
Competitor ratio analysis: Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; ADX10059; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; XP19986; Competitor ratio analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results
SOURCES
Espicom Sources
Others
List of Tables: Genes associated with IBD; IBD patient forecasts 2005-2012; Currently available aminosalicylates; Currently available corticosteroids; Immunosuppressants currently used in IBD; Drugs in developmentfor IBD; Competitor ratio analysis summary; Remicade sales, 2002-2006 (US$ millions); Humira sales, 2003-2006 (US$ millions); Currently available antidepressants; Drugs in development for IBS; Competitor ratio analysis summary; Competitor Ratio Score: 42; Sales of leading drugs used in GORD management (US$ millions); Approved H2 receptor antagonists; Gaster Sales, 2003-2007 (¥ & US$ million); Zantac sales, 2002-2006 (£ & US$ million); Approved proton pump inhibitors; AcipHex/Pariet sales, 2002-2006 (¥ & US$ million); Nexium sales, 2002-2006 (US$ million); Prevacid/Takepron sales, 2002-2006 (¥ & US$ million); Losec/Prilosec sales, 2002-2006 (US$ million); Protonix/Pantozol sales, 2002-2006 (EUR & US$ million); Drugs in development for GORD; Competitor ratio analysis summary
List of Figures: IBD prevalence 2007; Drugs in clinical development for IBD by activity; Remicade projected sales, 2006-2012 (US$ million); Humira projected sales 2006-2012 (US$ millions); Cimzia projected sales 2008-2012 (US$ millions); Golimumab projected sales, 2010-2014 (US$ million); ABT-874 projected sales, 2009-2014 (US$ millions); Amitiza, projected sales 2006-2012 (US$ millions); Gaster projected sales, 2007-2012 (US$ Million); Zantac projected sales, 2006-2012 (US$ million); AcipHex/Pariet projected sales, 2007-2012 (US$ million); Nexium projected sales, 2006-2012 (US$ million); Prevacid/Takepron projected sales, 2006-2012 (US$ million); Losec/Prilosec projected sales, 2006-2012 (US$ million); Protonix/Pantozol projected sales, 2006-2012 (US$ million)

Abstract

This new strategic report from Espicom provides a comprehensive review of current and future treatments for major gastrointestinal therapy areas: inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and gastro-oesophageal reflux disease (GORD). Over 145 pages of product analysis and forecasts

Unique market share and 5-year sales forecasts for leading products & prospects

A comprehensive examination of major gastrointestinal therapy areas

Critical competitive evaluation and scoring of current and up and coming products.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

advertise with us

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Gastrointestinal Drug Discoveries

Table of Contents

Abstract